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Background: Treatment options for patients with recurrent disease after radical prostatectomy include salvage
radiotherapy of the prostatic bed and/or androgen deprivation therapy. To establish an effective treatment strategy
for recurrent disease after radical prostatectomy, we retrospectively analyzed the outcome of salvage radiation
monotherapy in such cases.
Methods: Data from 61 men who had undergone salvage radiation monotherapy for biochemical recurrent disease
after radical prostatectomy were retrospectively reviewed. In all patients, salvage radiotherapy consisted of
iraradiation to the prostatic bed (70 Gy) using three-dimensional conformal radiotherapy techniques. Treatment
outcome was analyzed to identify predictive factors of salvage radiotherapy.
Results: The biochemical recurrence-free survival after salvage radiation monotherapy at 2 and 5 years was 55%
and 38%, respectively. Cox proportional regression models revealed that the independent predictive factors for
biochemical recurrence were Gleason Score ≥ 8, negative surgical margin, and PSA velocity ≥ 0.38 ng/mL/year.
Negative surgical margin and PSA velocity ≥ 0.8 ng/mL/year were significantly associated with poor response in
the serum PSA levels after salvage radiotherapy.
Conclusions: Based on our findings, we propose a treatment strategy for biochemical recurrent disease after radical
prostatectomy. Patients with Gleason score ≤ 7, positive surgical margin, and PSA velocity < 0.38 ng/mL/year are
categorized the most favorable group, so that eradication by salvage radiation monotherapy could be expected.
Other patients could be divided to two groups depending on surgical margin status and PSA velocity: 1) patients
who might require combination of SRT and short-term androgen deprivation therapy and 2) patients who should
be treated by androgen deprivation monotherapy.
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Radical prostatectomy is selected as the initial therapy in
44% of American men with prostate cancer (PCa) [1].
Our data from Nara Uro-Oncological Research Group
(NUORG) in Japan show an RP rate of approximately 30%
(40% in stage cT1-2N0M0) with rates of radiation therapy,
[2] but the proportion of radiation therapy is increasing
[3,4]. In case of stage cT1-2N0M0 PCa, the corresponding
figure was 40%es. Although RP provides excellent cancer
control, 15% to 40% of these men will experience recurrent
disease within 5 years presenting as an increasing serum
prostate-specific antigen (PSA) level without radiographic
evidence of cancer [5-8]. Extraprostatic extension, seminal
vesicle invasion and positive surgical margins are widely
recognized risk factors of recurrence after RP. Three large
randomized trials evaluating the role of post-RP adjuvant
radiotherapy for PCa with these risk factors have been
completed so far [9-11]. Adjuvant radiotherapy for patients
with high-risk PCa provides significant improvement of
biochemical recurrence (BCR)–free survival and clinical
recurrence–free survival. These results have raised debate
as to whether all patients with the risk factors should
receive immediate adjuvant radiotherapy, or whether close
surveillance and salvage radiotherapy (SRT) performed as
soon as BCR is detected can provide a similar benefit
and avoid overtreatment of men in whom disease
does not progress. SRT is the only salvage therapy
that can potentially achieve long-term freedom from
BCR and clinical progression [12-15].
A critical issue in the management of these patients is
to determine whether a rising serum PSA level after RP
represents isolated recurrence of the surgical prostate bed
or occult remote metastases that are undetectable by
imaging. The former can potentially be eradicated by
SRT. For the best chance of success, SRT of the surgical
site must be administered when the recurrent tumor
is localized and the tumor burden is low. Androgen-
deprivation therapy (ADT) seems to provide only palliation
to patients with recurrent prostate cancer.
To evaluate the benefit of SRT, we retrospectively reviewed
a patient cohort of men who had undergone SRT monother-
apy for the treatment of BCR after RP. We assessed their
BCR-free survival to identify which subgroup had the great-
est benefit from SRT, which subgroup needed combination
therapy with SRT and ADT, and which subgroup received
no benefit from SRT. To our knowledge, this is the first
study in which three different groups were set based on the
outcome of SRT to assess the clinicopathological background
and detect predictive factors for the outcome of SRT.
Materials and methods
Patients
There were 94 consecutive patients who underwent SRT
for the treatment of BCR after RP from January 2008 toDecember 2012 at Nara Medical University Hospital.
Among them, 33 patients (35.1%) received ADT before
the completion of SRT, including neoadjuvant therapy
prior to RP and adjuvant therapy after RP and were
excluded from analysis. Patient allocation was not
randomized, but depended on the clinician’s decision.
Thus for this study, we retrospectively reviewed the
medical records of 61 patients who did not undergo
ADT before the completion of SRT monotherapy. Medical
records were reviewed for relevant clinicopathological
information. Gleason score on prostate biopsy and radical
prostatectomy specimen reported tumor grade. The 2002
TNM classification was used for staging [16]. Furthermore,
patients were characterized into prognostic risk groups
based on the NCCN classification system [17]. In all
patients, digital rectal examination, pulmonary and
abdominal computed tomography, and bone scans were
performed before the initiation of SRT. No patients had
any findings suggesting of distant metastases.
PSA doubling time (PSADT) and PSA velocity
(PSAV) between the post-prostatectomy PSA nadir
and the initiation of SRT was calculated using at least
two PSA measurements with a 3-month interval and
log calculations on the website of the Memorial Sloan
Kettering Cancer Center (http://nomograms.mskcc.org/
Prostate/PsaDoublingTime.aspx).
The protocol for the research project was approved
by the Institutional Review Board for Clinical Studies
(Medical Ethics Committee) and the study was conducted
in compliance with the protocol and in accordance with
the provisions of the Declaration of Helsinki (2010).
Salvage radiotherapy (SRT)
SRT was defined as local radiotherapy to the prostatic
bed alone following BCR after RP. All patients managed
were seen at Nara Medical University Hospital and under-
went simulation prior to treatment with three-dimensional
conformal radiotherapy (3D-CRT) techniques with the
treatment fields encompassing the prostatic and seminal
vesicle bed plus periprostatic tissues. No attempt was made
to comprehensively irradiate pelvic lymph nodes. Per our
protocol, 70 Gy was delivered in daily fractions of 2.0 Gy.
The fields were shaped to protect the small bowels, bladder,
and posterior rectal wall.
Post-SRT evaluation
After SRT was completed, patients were evaluated by
measuring PSA every 3 to 4 months for 5 years, and
every 6 to 12 months thereafter. Median follow-up
period was 29.6 months (12.0 - 70.0). The primary endpoint
of this study was BCR after SRT. We divided the 61
patients into three groups according to the BCR status and
the progress of treatment (Figure 1). The first group was









   
   









   
   








   
   




Figure 1 Changes in serum PSA levels of patients who underwent salvage radiotherapy (SRT) for recurrent disease after radical
prostatectomy. Patients were evaluated by PSA measurement at regular intervals after completing SRT. Patients who showed a decline to
PSA < 0.2 ng/mL after SRT and maintained PSA < 0.2 ng/mL during the follow-up were categorized as the SRT success group (left). Patients who
showed a decline to PSA < 0.2 ng/mL after SRT and thereafter experienced a rise in PSA at two consecutive measurement points with the last
PSA≥ 0.2 ng/mL (middle) were categorized as the recurrence group. If the PSA continued to rise without a decline to PSA < 0.2 ng/mL after SRT, patients
were categorized as the nonresponse group (right). The recurrence group and the nonresponse group were defined as the SRT failure group.
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maintained PSA < 0.2 ng/mL during the follow-up (Figure 1,
left). The second group was defined as the recurrence
group, and consisted of patients who showed a decline to
PSA < 0.2 ng/mL after SRT, and then experienced a rise in
PSA at two consecutive measurement points to PSA ≥
0.2 ng/mL at the last two measurement points (Figure 1,
middle). The BCR date was defined as the first date with
PSA ≥ 0.2 ng/mL in the recurrence group. The third group
was defined as the nonresponse group. If the PSA contin-
ued to rise without a decline to PSA < 0.2 ng/mL after SRT,
it was considered as nonresponse to SRT (Figure 1, right).
The BCR date was the date of the completion of SRT in
the nonresponse group. The recurrence group and the
nonresponse group were categorized as the SRT failure
group (Figure 1, middle and right). All endpoints were
calculated from the date of the completion of SRT.
Statistical analysis
Student’s t-test, Mann Whitney U-test, the chi-square
test, and Fisher’s exact test were used to analyze the
clinicopathological variables. The correlation between
PSAV and PSADT was performed with Spearman’s
correlation analysis. BCR-free survival curves were
plotted according to the Kaplan Meier method, and the
log-rank test was applied for statistical significance. We
used multivariate Cox proportional hazards regression
models of several clinicopathological variables to identify
independent predictors of a poor response to SRT. The
association was evaluated using the odds ratio (OR) and
95% confidence interval (CI) derived by standard logistic
regression methods. For multivariate analysis, variables
were selected on the condition that the P value was less
than 0.1 in the univariate analysis. P values less than
0.05 were considered statistically significant. Statistical
analysis was performed with SPSS Statistical Package
version 20.0 (SPSS Inc., Chicago, IL).Results
A total of 31 (50.8%) out of 61 patients showed BCR
after SRT. The SRT failure group consisted of 16
patients in the recurrence group and 15 patients in the
nonresponse group. The BCR free-survival at 2 and
5 years, respectively, was 55% and 38% (Figure 2A). No
patients died of prostate cancer, but one patient died of
lung cancer during the follow-up. Grade 3 and 4 adverse
events after SRT were not observed. All patient character-
istics are listed and the statistical comparison of the SRT
success and SRT failure groups is shown in Table 1. There
were no differences between the SRT success group and
the SRT failure group according to age, initial PSA,
risk classification, prostatectomy Gleason score (GS),
pathological T stage, lymphatic invasion (ly), perineural
invasion (pn), or surgical margin status using contingency
table analysis (Table 1). However, univariate survival
analysis demonstrated that BCR after SRT had a significant
association with higher GS (Figure 2B, P = 0.047), while
positive surgical margin approached significance (Figure 2C,
P = 0.075). Among the PSA-related continuous values,
pre-SRT PSA and PSAV were significantly higher and
PSADT was significantly shorter in the SRT failure
groups compared to the SRT success groups. The optimal
cutoff of pre-SRT PSA, PSAV, and PSADT, respectively,
was set as 0.37 ng/mL, 0.38 ng/mL/year, and 6.0 months,
by testing all the data points yielding the highest p-value
in each intergroup comparison (Figure 2D-F). All three
values could be strong predictive parameters of BCR after
SRT over time. Since Spearman’s correlation analysis
showed that there was a high correlation between
PSAV and PSADT (P < 0.0001; r = −0.74, 95% confidence
interval −0.84 to −0.60) and PSAV was a better predictor
than PSADT (Figure 2E and F), PSAV was selected for
multivariate survival analysis. Multivariate Cox proportional
hazard analysis revealed that BCR was significantly
associated with GS ≥8 (HR 2.57, 95% CI 1.12-5.89), a
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Figure 2 Overall biochemical recurrence (BCR)-free survival. Kaplan-Meier estimates of BCR in all patients (A). Kaplan-Meier estimates of
biochemical recurrence (BCR)-free survival by prostatectomy Gleason score (B), surgical margin status (C), pre-SRT PSA (D), PSA velocity (E), and
PSA doubling time (F). Survival curves are compared using the log rank test. The time to biochemical recurrence is given in months.
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and PSAV ≥0.38 ng/mL/year (HR 4.44, 95% CI 1.58-12.5)
(Table 2). In the most favorable subgroup of patients with
GS ≤7, positive surgical margin, and PSAV < 0.38 ng/mL/
year, only one of 10 cases (10%) experienced BCR after
SRT, while in the least favorable group of patients GS >8,
negative surgical margin and PSAV >0.38 ng/mL/year, all
the four cases experienced BCR after SRT.
Next, we set out to determine which clinicopathological
parameters which could distinguish between the recurrence
group and the nonresponse group within the SRT failure
group. Three PSA-related values associated with BCR after
SRT were compared between the recurrence group and the
nonresponse group (Figure 3). While the PSADT did not
show any differences, there was a significant difference in
PSAV (P = 0.044) and a marginal difference in pre-SRT
PSA (P = 0.07). In a total of 31 cases consisting of 16 cases
in the recurrence group and 15 cases in the nonresponse
group, we determined optimal cut-off values of pre-SRT
PSA and PSAV using a dichotomous test. Pre-SRT
PSA ≥0.5 ng/mL and PSAV ≥0.8 ng/mL/year were
significant parameters distinguishing the nonresponse
group from the recurrence group (Table 3). Univariate
analysis revealed that only negative surgical margin
(odds ratio = 5.14; P = 0.038) was associated with nonre-
sponse to SRT. Multivariate logistic regression analysis also
identified negative surgical margin (odds ratio = 12.71;
P = 0.039) and PSAV ≥0.8 ng/mL/year (odds ratio = 12.14;P = 0.039) as independent predictors of a poor response
to SRT.
Discussion
Approximately one third of men undergoing RP for
curative intent of their PCa will experience BCR within
5 years following RP [5-9]. If salvage therapy is withheld,
two-thirds of recurrent cases will develop bone metastases
within 10 years of BCR [18]. Salvage therapies with the
intent to cure after BCR PCa consist of SRT and SRT
with concomitant ADT. ADT along with SRT or as
monotherapy should only be selected in cases that
cannot be cured with SRT monotherapy, because
ADT can have deleterious effects on the quality of
life, increased risks for serious health concerns, and
psychological distress [19,20]. However, there are uncer-
tainties about the optimal timing of SRT after RP (adjuvant
setting or salvage setting), especially in ethnic groups that
were not represented well in the three randomized trials
on post-operative radiation after RP [9-11].
In this study, we retrospectively reviewed a patient cohort
of men who had undergone SRT monotherapy to identify
prognostic factors for BCR after SRT. Our findings demon-
strated that GS 8 or more, negative surgical margin, and
PSAV ≥0.38 ng/mL/year were independent predictive
factors for poor SRT sensitivity (Table 3). Only one of
10 cases (10%) with three favorable factors (GS ≤7,
positive surgical margin, and PSAV <0.38 ng/mL/year)
Table 1 Characteristics of 61 patients undergoing SRT and comparison of SRT success group and SRT failure group
Variables Total (n = 61) SRT success
(n = 30)
SRT failure
(n = 31 )
SRT Success vs SRT
failure P value
Age at SRT (median, range) 69 (57–78) 70 (58–77) 69 (57–78) 0.88 †
Initial PSA (mean, SD) 12.5 ± 14.5 14.3 ± 19.7 10.7 ± 6.4 0.96 †
Clinical T stage 0.47 ‡
T1c 24 13 11
T2 29 12 17
T3 8 5 3
NCCN risk classification 0.086 ‡
Low 10 8 2
Intermidiate 28 11 17
High / Very high 23 11 12
Prostatectomy Gleason score 0.17 ‡
6 6 5 1
7 35 18 17
8 8 2 6
9 12 5 7
Prostatectomy pathological T stage 0.84 ‡
T2a 10 6 4
T2b 10 4 6
T2c 14 7 7
T3a / b 27 13 14
Prostatectomy lymphatic invasion (ly) 0.23 ‡
Negative 46 25 21
Positive 15 5 10
Prostatectomy perineural invasion (pn) 0.79 ‡
Negative 23 12 11
Positive 38 18 20
Prostatectomy Seminal vesicle involvement 0.97 ‡
Negative 57 28 29
Positive 4 2 2
Surgical margins 0.075 ‡
Negative 30 11 19
Positive 31 19 12
Time to PSA nadir after prostatectomy (months) 2.4 (0.8 - 17.9) 2.3 (0.8 - 15.8) 2.5 (0.9 - 17.9) 0.22 †
PSA nadir after prostatectomy (ng/mL) 0.140 ± 0.238 0.116 ± 0.214 0.163 ± 0.262 0.35 †
Pre-SRT PSA (ng/mL) 0.56 ± 0.49 0.37 ± 0.25 0.75 ± 0.59 0.021 †
PSAV after PSA recurrence (ng/mL/year) 0.19 ± 1.40 0.38 ± 0.40 1.43 ± 1.79 < 0.0001 †
PSADT after PSA recurrence (months) 7.44 ± 7.27 9.89 ± 9.02 5.07 ± 3.94 0.0049 †
Follow up period after SRT (months) 29.6 (12.0 - 70.0) 24.6 (12.0 - 70.0) 31.2 (12.0 - 64.6) 0.83 †
SRT = salvage radiotherapy; PSA = prostate-specific antigen; SD = standard deviation; NCCN = The National Comprehensive Cancer Network; PSAV = PSA velocity;
PSADT = PSA doubling time; † Man-Whitney U test; ‡ Chi-square test or Fisher’s exact test.
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with the three adverse factors (GS ≤ 8, negative surgical
margin and PSAV ≥0.38 experienced BCR after SRT. A
consensus report from the Genito-Urinary RadiationOncologists of Canada (GUROC) show that a number of
factors could predict disease progression: high GS, short
PSADT, high pre-SRT PSA, negative surgical margin, and
seminal vesicle involvement at the time of RP [15].
Table 2 Cox proportional models for SRT failure risks
Variables HR 95% CI P value
Prostatectomy Gleason score
6 / 7 1
8 / 9 2.57 1.12 - 5.89 0.026
Surgical margin
Positive 1
Negative 2.39 1.02 - 5.59 0.045
Pre-SRT PSA (ng/mL)
< 0.37 1
≥ 0.37 1.18 0.48 - 2.89 0.71
PSAV (ng/mL/year)
< 0.38 1
≥ 0.38 4.44 1.58 - 12.5 0.005
HR = Hazard ratio; CI = confidence interval; SRT = salvage radiotherapy;







































































Figure 3 Comparison of PSA-related values between the SRT
success group, recurrence group and nonresponse group.
Pre-SRT PSA (A), PSAV (B), and PSADT (C) were depicted by Tukey
box plots. Horizontal lines within boxes indicate median levels and
are depicted by horizontal lines within boxes. Significance (P < 0.05)
was assessed by the Mann–Whitney U test.
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were treated with ADT before the completion of SRT,
such as a neoadjuvant agents or adjuvant agents in
association with RP, were enrolled. Statistics can be
biased by the inclusion of patients who had undergone
ADT before the completion of SRT if disease progression
is defined as a rise in PSA. In our study, we excluded 33
patients who were treated with ADT before the comple-
tion of SRT, yielding 61 patients who were treated with
SRT monotherapy for recurrent disease after RP. The
exclusion enabled a unique analysis and identification
of clincopathological factors predicting SRT-success,
recurrence, and nonresponse groups.
SRT monotherapy should be selected for patients with
favorable factors while ADT alone could be selected for
patients in whom eradication of the recurrent disease
after RP is unlikely. Figure 4 shows a proposed treatment
strategy based on our findings. In patients harboring three
favorable factors including low GS, positive surgical
margin, and low PSAV, eradication by SRT monotherapy
can be expected. In contrast, in patients who do not meet
the conditions of favorable factors, it can be suspected
that radiation-resistant local recurrent tumor, remote
micro-metastases, or both may develop. It means that in
patients without the three favorable factors, SRT
monotherapy will likely prove inadequate to eradicate
recurrent disease. Thus these patients can be divided
according to the treatment progress into two groups:
those showing biochemical recurrence after a decline to
PSA < 0.2 ng/mL, and those presenting with nonre-
sponse to SRT. The former (positive surgical margins
or PSAV < 0.8) predominantly includes patients who
are unable to be salvaged by SRT monotherapy and
who require combination with short-term ADT. The latter
(negative surgical margins and PSAV ≥ 0.8) predominantly
Table 3 Univariate and multivariate analysis of factors in the SRT failure group that distinguish the nonresponse
group from the recurrence group
Variables
Univariate analysis Multivariate analysis †
OR 95% CI P value OR 95% CI P value
Prostatectomy Gleason score
6 / 7 1
8 / 9 0.5 0.12 - 2.14 0.35
Prostatectomy lymphatic invasion (ly)
Negative 1 1
Positive 3.79 0.75 - 19.1 0.097 2.95 0.30 - 29.4 0.36
Prostatectomy perineural invasion (pn)
Negative 1 1
Positive 4.00 0.81 - 19.8 0.081 3.56 0.47 - 26.8 0.22
Surgical margin
Positive 1 1
Negative 5.14 1.03 - 25.6 0.038 12.71 1.14 - 142.1 0.039
Pre-SRT PSA (ng/mL)
< 0.5 1
≥ 0.5 3.33 0.76 - 14.6 0.11
PSAV (ng/mL/year)
< 0.8 1 1
≥ 0.8 4.13 0.88 - 19.3 0.065 12.14 1.13 - 129.9 0.039
OR = Odds ratio; CI = confidence interval; SRT = salvage radiotherapy; PSAV = PSA velocity; † Logistic regression analysis.
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be treated by ADT monotherapy.
There are several limitations of the current study
including it being a retrospective study design with a
small sample size from a single-center and thereGleason score 7 and











Figure 4 Proposed treatment strategy for recurrent disease after radi
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